​​Clinical Study on Heavy Ion Therapy with Zero Out-of-Pocket Costs for Cervical Cancer Now Fully Launched​

As the first hospital in China to clinically apply a domestic heavy ion system and the only hospital globally operating two heavy ion systems, Gansu Wuwei Cancer Hospital has accumulated five years of clinical experience, treating over 2,000 patients across more than 50 conditions, including lung cancer, pancreatic cancer, and liver cancer. Clinical efficacy and patient survival rates have reached internationally advanced levels. The hospital has achieved "eight world and domestic firsts": the only hospital globally operating two heavy ion therapy systems; the hospital with the highest number of single-fraction treatments completed within one day; the first globally to develop precision heavy ion therapy under ventilator control; the first globally to implement bladder cancer treatment with precise bladder volume management; the first globally to perform single-session heavy ion therapy using surgically placed spacers between organs and tumors; the first in China to develop a 360° rotatable and adjustable ion therapy chair; the first globally to complete multiple cases of cardiac tumor treatment with heavy ions; and the first globally to integrate heavy ion therapy with comprehensive, lifelong physical and mental health management.

To further advance the high-quality development of heavy ion therapy in China, we are now launching the ​​"Phase II Single-Arm Clinical Study on Carbon Ion Therapy Combined with Brachytherapy for Locally Advanced Cervical Cancer"​​ based on our previous achievements. This study aims to establish China's clinical treatment standards for cervical cancer using heavy ion systems that meet international benchmarks, while pursuing better therapeutic outcomes for patients.

Phase II Single-Arm Clinical Study: Carbon Ion Therapy Combined with Brachytherapy for Locally Advanced Cervical Cancer​

​​Background

   Cervical cancer remains a prevalent malignancy affecting women worldwide. Traditional treatments show limited efficacy against locally advanced cases due to tumor progression and local infiltration.

Carbon ion radiotherapy delivers precise tumor targeting while sparing healthy tissues. Combined with brachytherapy, this approach may provide a more effective, lower-toxicity alternative. This study evaluates the clinical efficacy and safety of this combination therapy to identify optimal treatment strategies.

Inclusion Criteria​

1. Females aged 18-70 who voluntarily sign informed consent

2. Pathologically confirmed cervical cancer (FIGO 2018 Stage IIA2, IIB-IVA)

3. ECOG performance status 0-1; normal major organ (heart/liver/kidney) function; no severe comorbidities

4. Willingness to comply with treatment and follow-up requirements

Final eligibility determined by investigators per trial protocol

Patient Benefits​

1. Hospital-funded heavy ion therapy coverage

2. Personalized treatment plans by multidisciplinary (MDT) experts

3. Post-treatment follow-up monitoring and subsequent care planning

​​Contact Information

Wuwei Heavy Ion Center​​

   Dang Youquan: +86 138 9358 0468

​​Lanzhou Heavy Ion Center​​

   Zhao Fengju: +86 139 1921 9021